Invesco Ltd. Has $25.31 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Invesco Ltd. lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 21.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 205,480 shares of the specialty pharmaceutical company's stock after selling 55,493 shares during the quarter. Invesco Ltd. owned approximately 0.34% of Jazz Pharmaceuticals worth $25,305,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth approximately $25,000. Quadrant Capital Group LLC grew its position in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares during the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Allianz SE purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $29,000. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 130 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

JAZZ traded up $3.58 during trading hours on Thursday, hitting $107.77. 265,625 shares of the stock were exchanged, compared to its average volume of 790,758. The stock has a market cap of $6.55 billion, a price-to-earnings ratio of 15.18, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The stock has a 50-day simple moving average of $125.63 and a 200-day simple moving average of $122.18. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JAZZ. Truist Financial lifted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the company from $145.00 to $179.00 in a research note on Friday, March 7th. HC Wainwright lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Barclays restated an "overweight" rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $187.71.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now directly owns 8,237 shares in the company, valued at $1,189,587.54. The trade was a 36.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares of the company's stock, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock worth $4,023,305 over the last quarter. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.